RFO
GILD icon

RiverGlades Family Offices’s Gilead Sciences GILD Stock Holding History

RiverGlades Family Offices’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,188
Closed -$240K – 74
2018
Q1 		$240K Buy
+3,188
New +$253K 0.19% 68

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RiverGlades Family Offices's GILD Position: Q2 2018 in Review

RiverGlades Family Offices sold out of Gilead Sciences (GILD) in Q2 2018, closing a stake of 3,188 shares — an estimated $240K sold.

RiverGlades Family Offices first reported a position in GILD in Q1 2018 and held it in 1 quarter. The position peaked at $240K in Q1 2018. 1,523 funds tracked by Wall St. Rank hold GILD as of Q2 2018.

  • RiverGlades Family Offices reported no remaining Gilead Sciences position as of Q2 2018 after selling out during the quarter.
  • RiverGlades Family Offices sold 3,188 Gilead Sciences shares in Q2 2018, an estimated $240K.
  • RiverGlades Family Offices first reported a position in Gilead Sciences in Q1 2018 and held it in 1 quarter.
  • RiverGlades Family Offices's Gilead Sciences position peaked at $240K in Q1 2018.
  • 1,523 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2018.

Based on RiverGlades Family Offices's 13F filing for Q2 2018, filed 14 Aug 2018.